Skip to main content

Compare Stocks

Date Range: 

 Arcutis BiotherapeuticsZealand Pharma A/SApplied Molecular TransportOlema PharmaceuticalsCara Therapeutics
SymbolNASDAQ:ARQTNASDAQ:ZEALNASDAQ:AMTINASDAQ:OLMANASDAQ:CARA
Price Information
Current Price$25.75$29.00$44.70$25.11$13.20
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.22.01.61.8
Analysis Score3.53.53.53.53.5
Community Score2.22.53.64.33.1
Dividend Score0.00.00.00.00.0
Ownership Score1.70.02.50.01.7
Earnings & Valuation Score0.60.00.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$54.67$43.00$68.75$60.67$32.00
% Upside from Price Target112.30% upside48.28% upside53.80% upside141.60% upside142.42% upside
Trade Information
Market Cap$1.29 billion$1.26 billion$1.58 billion$1.01 billion$660.69 million
BetaN/A1.19N/AN/A1.7
Average Volume265,42711,822227,360152,3161,051,990
Sales & Book Value
Annual RevenueN/A$6.20 millionN/AN/A$19.89 million
Price / SalesN/A203.23N/AN/A33.22
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/A$5.85 per shareN/AN/A$4.66 per share
Price / BookN/A4.96N/AN/A2.83
Profitability
Net Income$-42,000,000.00$-85,670,000.00$-28,040,000.00N/A$-106,370,000.00
EPS($22.78)($2.54)N/AN/A($2.49)
Trailing P/E RatioN/AN/A0.000.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-214.31%N/AN/A-360.35%
Return on Equity (ROE)-81.74%-38.34%N/AN/A-64.36%
Return on Assets (ROA)-57.72%-30.40%N/AN/A-53.22%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio9.18%6.76%19.39%N/A8.00%
Quick Ratio9.18%6.51%19.39%N/A8.00%
Ownership Information
Institutional Ownership Percentage79.63%4.32%51.99%N/A67.01%
Insider Ownership PercentageN/AN/AN/AN/A5.70%
Miscellaneous
Employees54329803680
Shares Outstanding50.21 million43.45 million35.25 million40.17 million50.05 million
Next Earnings Date8/10/2021 (Estimated)8/12/2021 (Estimated)8/10/2021 (Estimated)8/10/2021 (Estimated)8/9/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Cara Therapeutics, Inc. 2021 Q1 - Results - Earnings Call PresentationCara Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 13 at 4:50 PM
Jefferies Financial Group Analysts Raise Earnings Estimates for Cara Therapeutics, Inc. (NASDAQ:CARA)Jefferies Financial Group Analysts Raise Earnings Estimates for Cara Therapeutics, Inc. (NASDAQ:CARA)
americanbankingnews.com - May 13 at 10:44 AM
Piper Sandler Analysts Boost Earnings Estimates for Cara Therapeutics, Inc. (NASDAQ:CARA)Piper Sandler Analysts Boost Earnings Estimates for Cara Therapeutics, Inc. (NASDAQ:CARA)
americanbankingnews.com - May 13 at 9:30 AM
Cara Therapeutics EPS beats by $0.12, misses on revenueCara Therapeutics EPS beats by $0.12, misses on revenue
seekingalpha.com - May 12 at 11:10 PM
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q1 2021 Results - Earnings Call TranscriptCara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 6:09 PM
Piper Sandler Weighs in on Cara Therapeutics, Inc.s FY2024 Earnings (NASDAQ:CARA)Piper Sandler Weighs in on Cara Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:CARA)
americanbankingnews.com - May 12 at 7:56 AM
Cara Therapeutics (NASDAQ:CARA) Announces Quarterly  Earnings ResultsCara Therapeutics (NASDAQ:CARA) Announces Quarterly Earnings Results
americanbankingnews.com - May 11 at 3:38 PM
Cara Therapeutics Inc (CARA) Q1 2021 Earnings Call TranscriptCara Therapeutics Inc (CARA) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 11 at 12:49 AM
Cara: Q1 Earnings SnapshotCara: Q1 Earnings Snapshot
sfgate.com - May 10 at 7:48 PM
BRIEF-Cara Therapeutics Reports Q1 Loss Per Share $0.47BRIEF-Cara Therapeutics Reports Q1 Loss Per Share $0.47
msn.com - May 10 at 7:48 PM
Cara Therapeutics: Q1 Earnings InsightsCara Therapeutics: Q1 Earnings Insights
benzinga.com - May 10 at 7:48 PM
Cara Therapeutics Reports First Quarter 2021 Financial ResultsCara Therapeutics Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 10 at 7:48 PM
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue EstimatesCara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 10 at 7:48 PM
Cara Therapeutics (NASDAQ:CARA) Reaches New 1-Year Low at $12.16Cara Therapeutics (NASDAQ:CARA) Reaches New 1-Year Low at $12.16
americanbankingnews.com - May 10 at 4:14 PM
Cara Therapeutics Inc. (NASDAQ:CARA) Climbs 107% In 2021; Is It Attractive Enough At $12.56?Cara Therapeutics Inc. (NASDAQ:CARA) Climbs 107% In 2021; Is It Attractive Enough At $12.56?
marketingsentinel.com - May 8 at 7:31 PM
FY2022 Earnings Forecast for Cara Therapeutics, Inc. (NASDAQ:CARA) Issued By Cantor FitzgeraldFY2022 Earnings Forecast for Cara Therapeutics, Inc. (NASDAQ:CARA) Issued By Cantor Fitzgerald
americanbankingnews.com - May 7 at 9:24 AM
Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care ConferenceCara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
finance.yahoo.com - May 6 at 6:33 PM
Here is a bargain stock you should look at : Cara Therapeutics Inc. (CARA)Here is a bargain stock you should look at : Cara Therapeutics Inc. (CARA)
marketingsentinel.com - May 5 at 5:32 PM
Needham & Company LLC Lowers Cara Therapeutics (NASDAQ:CARA) Price Target to $26.00Needham & Company LLC Lowers Cara Therapeutics (NASDAQ:CARA) Price Target to $26.00
americanbankingnews.com - May 5 at 3:27 PM
Cara Therapeutics (NASDAQ:CARA) Hits New 1-Year Low at $12.26Cara Therapeutics (NASDAQ:CARA) Hits New 1-Year Low at $12.26
americanbankingnews.com - May 4 at 9:02 PM
Cara Therapeutics (CARA) to Release Earnings on MondayCara Therapeutics (CARA) to Release Earnings on Monday
americanbankingnews.com - May 4 at 12:04 PM
Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseCara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
finance.yahoo.com - May 3 at 7:53 PM
Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
finance.yahoo.com - May 3 at 7:53 PM
Short Interest in Cara Therapeutics, Inc. (NASDAQ:CARA) Expands By 30.7%Short Interest in Cara Therapeutics, Inc. (NASDAQ:CARA) Expands By 30.7%
americanbankingnews.com - May 3 at 1:08 AM
Cara Therapeutics Inc. [CARA] Is Currently -45.44 below its 200 Period Moving Avg: What Dose This Mean?Cara Therapeutics Inc. [CARA] Is Currently -45.44 below its 200 Period Moving Avg: What Dose This Mean?
dbtnews.com - April 30 at 10:59 PM
Cara Therapeutics (NASDAQ:CARA) Price Target Lowered to $26.00 at Needham & Company LLCCara Therapeutics (NASDAQ:CARA) Price Target Lowered to $26.00 at Needham & Company LLC
marketbeat.com - April 29 at 2:09 PM
DateCompanyBrokerageAction
2/2/2021Arcutis BiotherapeuticsTruistBoost Price Target
2/1/2021Arcutis BiotherapeuticsCowenBoost Price Target
1/28/2021Arcutis BiotherapeuticsJonestradingInitiated Coverage
11/9/2020Arcutis BiotherapeuticsThe Goldman Sachs GroupUpgrade
3/20/2020Arcutis BiotherapeuticsCantor FitzgeraldReiterated Rating
2/25/2020Arcutis BiotherapeuticsGuggenheimInitiated Coverage
11/13/2020Zealand Pharma A/SMorgan StanleyLower Price Target
8/13/2020Zealand Pharma A/SNeedham & Company LLCInitiated Coverage
11/27/2019Zealand Pharma A/SJefferies Financial GroupDowngrade
3/23/2021Applied Molecular TransportJMP SecuritiesInitiated Coverage
2/25/2021Applied Molecular TransportSVB LeerinkBoost Price Target
6/30/2020Applied Molecular TransportBank of AmericaInitiated Coverage
12/14/2020Olema PharmaceuticalsJPMorgan Chase & Co.Initiated Coverage
12/14/2020Olema PharmaceuticalsCanaccord GenuityInitiated Coverage
4/21/2020Cara TherapeuticsHC WainwrightBoost Price Target
7/30/2019Cara TherapeuticsPiper Jaffray CompaniesBoost Price Target
5/29/2019Cara TherapeuticsLaidlawBoost Price Target
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.